Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Volpara Health Technologies.
RELATED STOCKHEAD STORIES
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall in first week of FY23 as Mach 7 scores biggest deal in its history
Health & Biotech
Which ASX health companies are making strides in world’s largest healthcare market?
Health & Biotech
ASX Health Stocks: US FDA happy to review anal fissure drug; gives green light to Clarity’s Phase 3 trial
Health & Biotech
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Tech
The ASX tech stocks set to reap benefits of positive cash flow
News
Market Highlights: The SEC goes after Coinbase; Goldman slashes its iron ore price forecast
Health & Biotech
4D Medical’s technology disrupts century-old procedures AND makes over 90pc profit margin
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall as investors fail to reward good news
News
Market Highlights: ASX to crumble after shares slump in US and Europe; Nvidia hits ATH amid AI frenzy
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, Immutep surges 46pc on trial results
Health & Biotech
ScoPo’s (he’s back) Powerplays: ASX health stocks fall, Volpara ‘elephants’ strategy pays off
Health & Biotech
ASX Health Stocks: Atomo and Volpara strike $1m+ contracts; Estia tells Bain to improve $3 offer
Health & Biotech
Why growth is a positive for the ASX medical imaging sector
News
Rise and Shine: Everything you need to know before the ASX opens
News
Chasing elephants: How Volpara’s new CEO is making this cancer fighter profitable for future growth
Health & Biotech
ASX Health Stocks: Volpara jumps 10pc as US FDA makes new ruling on ‘dense breasts’ language
Stockhead TV